GlassScriptPhysician profile
Bindu Asok Kumar
NPI 1114463791
$7,704.96
in general payments reported to CMS, 2019-2025
55 companies · $16.34 in 2025
The $16.34 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,269 · 2022: $2,485 · 2023: $2,887 · 2024: $1,048 · 2025: $16.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,951.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $750.41 | 2021-2024 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $682.59 | 2021-2024 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $511.53 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $457.03 | 2021-2024 | |
| Incyte Corporation | $419.79 | 2021-2024 | Jakafi, Monjuvi |
| Seagen INC. | $419.39 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $382.72 | 2021-2023 | Darzalex, Tecvayli, Imbruvica |
| Pfizer INC. | $294.75 | 2021-2024 | |
| Gilead Sciences, INC. | $275.40 | 2022-2024 | Trodelvy |
| Array Biopharma INC | $242.32 | 2021-2023 | Braftovi, Lorbrena, Mektovi |
| Eisai INC. | $229.93 | 2022-2024 | |
| Taiho Oncology, INC. | $220.71 | 2022-2024 | |
| Amgen INC. | $202.20 | 2021-2023 | Lumakras |
| Lilly USA, LLC | $193.46 | 2022-2023 | Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $178.11 | 2021-2023 | Imbruvica |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Asok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.